Volume 13, Issue 2 (8-1999)                   Med J Islam Repub Iran 1999 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
YADEGARI D, TALAIE H, MASSOUD J. CLINICAL TRIAL OF TRICLABENDAZOLE ON HUMAN FASCIOLIASIS: LONG TERM FOLLOW UP. Med J Islam Repub Iran 1999; 13 (2) :89-91
URL: http://mjiri.iums.ac.ir/article-1-946-en.html
CLINICAL TRIAL OF TRICLABENDAZOLE ON HUMAN FASCIOLIASIS: LONG TERM FOLLOW UP
D YADEGARI , H TALAIE , J MASSOUD
From the Shahid Beheshti University of Medical Sciences & Health Services, the WHO Collaborating Center for Educational Development of Medical & Health Personnel (EDC); and the School of Public Health, Tehran Medical Sciences University, PO. Box 6446-14155, Tehran, 1R. Iran. , talaie@hotmail. com
Abstract:   (4555 Views)
Following an outbreak: of human fascioliasis in Gilan province of Iran in 1989, the benzimidazole derivative triclabendazole (TCBZ) was suggested as the drug of choice after finding out that routine drugs were not effective. Two studies were performed: a clinical trial (before/after type) in 1989 and a historical cohort (1989- 1995) to examine the efficacy of the drug. TCBZ was administered to 94 patients in four groups (A, B, C and D) according to the drug's instructions (time, size and frequency of dose). The patients were followed up clinically and paraclinically for 60 days. The highest cure rate, i.e. , omission of eggs and improvement of clinical symptoms (86.6%) was observed in Group A (5 mg/kg-NPO, 3 days). Minor epigastric pain and vomiting and some urticaria was reported a few days after administration of the drug. Just a few developed cholangitis and one toxic hepatitis who were all treated satisfactorily. The second study was a 6-year follow-up survey of 50 of the 94 patients. Five cases had epigastric pain, and eggs were detected in the stool exams of two of them. Thus, by demonstrating up to 94% efficacy in the treatment of human fascioliasis in Iran (p<0.002), TCBZ is recommended as the drug of choice.
Full-Text [PDF 359 kb]   (2427 Downloads)    
Type of Study: Original Research | Subject: Health
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.